5 Companies Hit 52-Week Highs

GuruFocus.com
0
In this article:

- By yifan900

According to GuruFocus list of 52-week highs , these Guru stocks have reached their 52-week highs.

Abbott Laboratories (NYSE:ABT) reached the 52-week high of $69.05


Abbott Laboratories is a health care company that manufactures medical devices, blood glucose monitoring kits, nutritional healthcare products, diagnostic products and equipment, and branded generic drugs. Abbott manufactures and markets medical devices, blood glucose monitoring kits, nutritional healthcare products, diagnostic products and equipment, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, coronary stents, catheters, infant formula, nutritional liquids for adults, vessel closure devices, and Lasik equipment. Abbott derives approximately 60% of sales outside the U.S.

The price of Abbott Laboratories shares has reached $69.05, which is 0.3% off the 52-week high of $69.25. Abbott Laboratories has a market cap of $121.14 billion; its shares were traded around $69.05 with a price-earnings ratio of 138.10 and price-sales ratio of 4.11. The trailing 12-month dividend yield of Abbott Laboratories stocks is 1.60%. The forward dividend yield of Abbott Laboratories stocks is 1.62%. Abbott Laboratories had an annual average earnings growth of 9.10% over the past five years.

Abbott recently announced financial results for the second quarter ended June 30, 2018. Results include:

  • Second-quarter worldwide sales of $7.8 billion increased 17% on a reported basis and 8% on an organic basis.

  • Reported diluted earnings per share from continuing operations under GAAP were 40 cents in the second quarter.

  • Adjusted diluted earnings per share from continuing operations, which excludes specified items, was 73 cents.



Executive Vice President Brian J. Blaser sold 58,200 shares of Abott Laboratories stock on Sept. 20, 2018 at the price of $68.79 per share. The price of the stock has increased by 0.38% since.

ConocoPhillips (NYSE:COP) reached the 52-week high of $76.28

ConocoPhillips operates in the oil & gas sector. Its primary business involves exploration and production of crude oil and natural gas. ConocoPhillips is a U.S.-based independent exploration and production firm. In 2017, it produced 832,000 barrels per day of oil and natural gas liquids and 3.3 billion cubic feet per day of natural gas, primarily from the United States, Canada, Norway and the U.K. Proven reserves at year-end 2016 stood at 5 billion barrels of oil equivalent.

The price of ConocoPhillips shares has reached $76.28, which is 0.5% off the 52-week high of $76.66. ConocoPhillips has a market cap of $88.64 billion; its shares were traded around $76.28 with a price-earnings ratio of 20.29 and price-sales ratio of 2.83. The trailing 12-month dividend yield of ConocoPhillips stocks is 1.47%. The forward dividend yield of ConocoPhillips stocks is 1.49%.

ConocoPhillips recently reported second-quarter 2018 earnings of $1.6 billion, or $1.39 per share, compared with a second-quarter 2017 loss of $3.4 billion, or $2.78 per share. Excluding special items, second-quarter 2018 adjusted earnings were $1.3 billion, or $1.09 per share, compared with second-quarter 2017 adjusted earnings of 200 million, or 14 cents per share.

Vice President and Controller Glenda Mae Schwarz sold 18,882 shares of ConocoPhillips stock on Sept. 10, 2018, at the price of $71.15 per share. The price of the stock has increased by 7.21% since.

Xylem Inc. (NYSE:XYL) reached the 52-week high of $81.22

Xylem Inc. is an industrial technology company. It provides equipment, technology and services to transport, treat, test and efficiently use water in public utilities, residential and commercial buildings, and industrial and agricultural settings. Xylem is a leading global provider of equipment, technology, and services to transport, treat, test, and efficiently use water in public utilities, residential and commercial buildings, and industrial and agricultural settings. Based in Rye Brook, New York, Xylem operates in more than 150 countries through market- leading brands and has broad applications expertise tackling difficult water and wastewater problems. Xylem generated 2016 revenue and adjusted operating income of $3.8 billion and $511 million, respectively, and employs 12,700 people.

The price of Xylem Inc. shares has reached $81.22, which is 1.5% off the 52-week high of $82.44. Xylem Inc. has a market cap of $14.59 billion; its shares were traded around $81.22 with a price-earnings ratio of 39.81 and price-sales ratio of 2.94. The trailing 12-month dividend yield of Xylem Inc. stocks is 1.00%. The forward dividend yield of Xylem Inc. stocks is 1.03%. Xylem Inc. had an annual average earnings growth of 5.90% over the past five years.

Xylem Inc. recently reported second quarter 2018 net income of $115 million, or 64 cents per share. Excluding the impact of restructuring, realignment and other special items, the Company delivered adjusted net income of $131 million or 73 cents per share in the quarter, a 24% increase over the prior year period. Second quarter revenue was $1.3 billion, up 13% including the impact of foreign exchange and acquisitions.

Senior Vice President Colin R. Sabol sold 17,161 shares of Xylem stock on Sept. 17, 2018 at the price of $81.37 per share. The price of the stock has decreased by 0.18% since.

The Cooper Companies Inc. (NYSE:COO) reached the 52-week high of $268.93

Cooper Companies Inc. is a medical device company operating through its subsidiaries. It manufactures products for contact lens wearers and supplies women's health clinicians with products and treatment options to improve the delivery of health care. Cooper Companies operates two units: CooperVision and CooperSurgical. Accounting for over 80% of total sales, CooperVision is one of the world's top four developers and manufacturers of contact lenses. Over 50% of CooperVision's sales are in international territories. At roughly 20% of total sales, CooperSurgical develops and manufactures diagnostic and surgical products for gynecologists and obstetricians.

The price of The Cooper Companies Inc. shares has reached $268.93, which is 0.6% off the 52-week high of $270.64. The Cooper Companies Inc. has a market cap of $13.22 billion; its shares were traded around $268.93 with a price-earnings ratio of 105.88 and price-sales ratio of 5.45. The trailing 12-month dividend yield of The Cooper Companies Inc. stocks is 0.02%. The forward dividend yield of The Cooper Companies Inc. stocks is 0.02%. The Cooper Companies Inc. had an annual average earnings growth of 12.60% over the past 10 years. GuruFocus rated The Cooper Companies Inc. the business predictability rank of 4-star .

The Cooper Companies Inc. recently announced financial results for the fiscal third quarter ended July 31, 2018. Results include:

  • Revenue increased 19% year-over-year to $660.0 million.

  • GAAP diluted earnings per share $2.03, down 6 cents or 2.9% from last year's third quarter.

  • Non-GAAP diluted earnings per share $3.00, up 36 cents or 14% from last year's third quarter.



Director Robert S. Weiss sold 58,543 shares of Cooper Companies stock on Sept. 5, 2018, at the price of $252.82 per share. The price of the stock has increased by 6.37% since. Executive Vice President, Chief Operating Officer and President CooperVision Daniel G. McBride sold 10,310 shares of Cooper Companies stock on Sept. 13, 2018, at the price of $264.44 per share. The price of the stock has increased by 1.7% since.

Illumina Inc. (NASDAQ:ILMN) reached the 52-week high of $358.16

Illumina Inc. engages in life science tools and machines for analyzing genetic material. The company primarily engages in microarray and genome sequencing machines and disposables. It also provides sequencing services through its products. Illumina Inc. is a major player in life science tools for analyzing genetic material. Revenue from microarray and genome sequencing machines and disposables make up most of the company's revenue, but approximately 10% of the company's sales come from sequencing services. Essentially all of Illumina's growth stems from the company's genome sequencing products, which include the company's high-throughput NovaSeq and HiSeq instruments in addition to its benchtop NextSeq, MiSeq, MiniSeq and iSeq product lines.

The price of Illumina Inc. shares has reached $358.16, which is 0.7% off the 52-week high of $360.63. Illumina Inc. has a market cap of $52.65 billion; its shares were traded around $358.16 with a price-earnings ratio of 81.40 and price-sales ratio of 17.08. Illumina Inc. had an annual average earnings growth of 34.30% over the past 10 years. GuruFocus rated Illumina Inc. the business predictability rank of 4-star .

Illumina Inc. recently announced its financial results for the second quarter of fiscal year 2018. Second quarter 2018 results include:

  • Revenue of $830 million, a 25% increase compared to $662 million in the second quarter of 2017.

  • GAAP net income attributable to Illumina stockholders for the quarter of $209 million, or $1.41 per diluted share, compared to $128 million, or 87 cents per diluted share, for the second quarter of 2017.

  • Non-GAAP net income attributable to Illumina stockholders for the quarter of $212 million, or $1.43 per diluted share, compared to $121 million, or 82 cents per diluted share, for the second quarter of 2017.

  • Cash flow from operations of $295 million compared to $178 million in the second quarter of 2017.



President and CEO Francis A Desouza sold 2,100 shares of Illumina stock on Sept. 4, 2018, at the price of $353.66 per share. The price of the stock has increased by 1.27% since. Senior Vice President and Chief Technology Officer Mostafa Ronaghi sold 10,000 shares of Illumina stock on Sept. 10, 2018, at the price of $347.07 per share. The price of the stock has increased by 3.2% since.


Note: I do not own any of the stocks discussed.

This article first appeared on GuruFocus.


Advertisement

Recommended Stories